Nicholas Rebold, Sara Alosaimy, Jeffrey C Pearson, Brandon Dionne, Ahmad Taqi, Abdalhamid Lagnf, Kristen Lucas, Mark Biagi, Nicholas Lombardo, Joshua Eudy, Daniel T Anderson, Monica V Mahoney, Wesley D Kufel, Joseph A D'Antonio, Bruce M Jones, Jeremy J Frens, Tyler Baumeister, Matthew Geriak, George Sakoulas, Dimitrios Farmakiotis, Dino Delaportas, Jeremy Larew, Michael P Veve, Michael J Rybak
INTRODUCTION: Long-acting lipoglycopeptides such as dalbavancin may have utility in patients with Gram-positive bloodstream infections (BSI), particularly in those with barriers to discharge or who require prolonged parenteral antibiotic courses. A retrospective cohort study was performed to provide further multicenter real-world evidence on dalbavancin use as a sequential therapy for Gram-positive BSI. METHODS: One hundred fifteen patients received dalbavancin with Gram-positive BSI, defined as any positive blood culture or diagnosed with infective endocarditis, from 13 centers geographically spread across the United States between July 2015 and July 2021...
March 1, 2024: Infectious Diseases and Therapy